Clinical solutions
Powering clinical diagnostics with future-proof AI
Breast Cancer Suite
The AI model supports the histological grading of breast cancer in whole slide images (WSI) of H&E stained tissue biopsies. It detects invasive carcinoma and ductal carcinoma in situ (DCIS) and scores the grading components mitotic count, tubulus formation, and nuclear pleomorphism. It has been designed based on the Nottingham Grading System.
Aiforia® Breast Cancer Grading is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
The AI model supports the detection of invasive carcinoma and scoring of Ki67 positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time in the whole slide image scoring (up to 55% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
The AI model supports the detection of invasive carcinoma and scoring of ER positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Saved time (up to 47% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
The AI model supports the detection of invasive carcinoma and scoring of PR positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Saved time (up to 16% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
The Al model supports the detection of invasive carcinoma and scoring of HER2 positivity and intensity in tumor cells from whole slide images
(WSI) of breast tissue. The Al model has been designed according to CAP recommendations for HER2 analysis.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time (up to 16% faster)
Aiforia® Breast Cancer HER2 is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Breast Cancer Suite
Aiforia® Breast Cancer Grading
The AI model supports the histological grading of breast cancer in whole slide images (WSI) of H&E stained tissue biopsies. It detects invasive carcinoma and ductal carcinoma in situ (DCIS) and scores the grading components mitotic count, tubulus formation, and nuclear pleomorphism. It has been designed based on the Nottingham Grading System.
Aiforia® Breast Cancer Grading is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Aiforia® Breast Cancer Ki67
The AI model supports the detection of invasive carcinoma and scoring of Ki67 positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time in the whole slide image scoring (up to 55% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
Aiforia® Breast Cancer ER
The AI model supports the detection of invasive carcinoma and scoring of ER positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Saved time (up to 47% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
Aiforia® Breast Cancer PR
The AI model supports the detection of invasive carcinoma and scoring of PR positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Saved time (up to 16% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
Aiforia® Breast Cancer HER2
The Al model supports the detection of invasive carcinoma and scoring of HER2 positivity and intensity in tumor cells from whole slide images
(WSI) of breast tissue. The Al model has been designed according to CAP recommendations for HER2 analysis.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time (up to 16% faster)
Aiforia® Breast Cancer HER2 is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Lung Cancer Suite
The AI model supports the detection of invasive carcinoma areas in patient samples and the scoring of PD-L1 negative and positive tumor cells in non-small cell lung (NSCLC) cancer cases.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time (up to 46% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
Lung Cancer Suite
Aiforia® Lung Cancer PD-L1
The AI model supports the detection of invasive carcinoma areas in patient samples and the scoring of PD-L1 negative and positive tumor cells in non-small cell lung (NSCLC) cancer cases.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time (up to 46% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
Prostate Cancer Suite
The AI model supports the detection of adenocarcinoma and assists Gleason grade grouping from whole slide images (WSI).
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Saved time (up to 36% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
The AI model supports the detection of perineural invasion (PNI) in whole slide images (WSI) of prostate tissue.
Aiforia® Prostate Cancer PNI is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
The AI model supports the detection of Gleason 4 cribriform pattern in whole slide images (WSI) of prostate tissue.
Aiforia® Prostate Cancer G4 cribriform is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
The AI model supports the detection of high-grade prostatic intraepithelial neoplasia (high-grade PIN) in whole slide images (WSI) of prostate tissue.
Aiforia® Prostate Cancer HG-PIN is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Prostate Cancer Suite
Aiforia® Prostate Cancer Gleason Grade Groups
The AI model supports the detection of adenocarcinoma and assists Gleason grade grouping from whole slide images (WSI).
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Saved time (up to 36% faster)
CE-IVD marked for diagnostic use in EU and EEA countries
Aiforia® Prostate Cancer PNI
The AI model supports the detection of perineural invasion (PNI) in whole slide images (WSI) of prostate tissue.
Aiforia® Prostate Cancer PNI is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Aiforia® Prostate Cancer G4 cribriform
The AI model supports the detection of Gleason 4 cribriform pattern in whole slide images (WSI) of prostate tissue.
Aiforia® Prostate Cancer G4 cribriform is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Aiforia® Prostate Cancer HG-PIN
The AI model supports the detection of high-grade prostatic intraepithelial neoplasia (high-grade PIN) in whole slide images (WSI) of prostate tissue.
Aiforia® Prostate Cancer HG-PIN is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Colon Suite
The prognostic AI model identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for treatment decisions. The AI model was developed and validated in collaboration with the Mayo Clinic.
Clinical Validation
- Verified and validated in the Aiforia® Platform using whole slide images from eight independent hospitals and patient cohorts
- Improved risk stratification as compared to the American Society of Clinical Oncology staging
Aiforia® Colorectal Cancer QuantCRC is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Colon Suite
Aiforia® Colorectal Cancer QuantCRC
The prognostic AI model identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for treatment decisions. The AI model was developed and validated in collaboration with the Mayo Clinic.
Clinical Validation
- Verified and validated in the Aiforia® Platform using whole slide images from eight independent hospitals and patient cohorts
- Improved risk stratification as compared to the American Society of Clinical Oncology staging
Aiforia® Colorectal Cancer QuantCRC is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.
Increased efficiency
Diagnose more patients in less time by unbinding yourself from time-consuming, manual tasks.
Advanced precision
Improve diagnostic accuracy and be confident in your decision-making.
Improved consistency
Reduce variability to standardize your sample review and ensure democratized patient care.
Future-proof
Together with our customers, we continue to develop new groundbreaking AI models, with thousands of models already developed for research use. We’re committed to providing cutting-edge deep learning AI models designed to meet the evolving needs of our customers. As clinical diagnostics become increasingly complex, our advanced software will ensure you stay at the forefront of technology.
Transparency
Aiforia makes a commitment to keeping our AI algorithms transparent and understandable. You remain in control, see how analyses are conducted, and participate in the training process. AI models serve as first-read support while the expert verifies the results. We offer our customers with fully quantifiable data and results that can easily be adjusted.
Ease of use
The Aiforia software requires no data scientists or coding expertise. Our team of experts integrates the solutions into existing IT infrastructures. We acknowledge that every lab is different, so we optimize each model for each lab’s individual needs and monitor their performance to deliver continuous improvement. Aiforia’s software allows customers to confidently scale up their operations while paying only for what they need.
Security
We take data privacy and security very seriously. We hold several globally relevant quality and security certifications, so our customers can be sure their sample and patient data is safe.* Customers determine what information is stored in the cloud and can opt for a private version.
*Our image analysis solutions are developed and maintained securely per ISO 27001 and SOC 2 Type II security standards, and ISO 13485 quality standards. In addition, we strictly adhere to GDPR requirements and all applicable HIPAA policies and procedures.
Integration services
Integration can be straightforward. Aiforia solutions can be integrated with any existing laboratory infrastructure to enjoy the full benefits of a digitized workflow.
Cloud hosting services
Choose to host on our secure shared or private cloud environment. You can also opt to host on your own cloud provider (preferred partners include MS Azure and GCP).
Custom AI services
AI models developed by scientists, for scientists. With custom AI services, Aiforia's scientists build AI models for your specific needs.
Case studies, resources and more
AI for clinical diagnostics
/Cancer%20JPEG/prostate_grading_after.jpeg?width=600&height=343&name=prostate_grading_after.jpeg)
INTERVIEW
Benefits of AI and digital pathology to the clinical lab
We interviewed two pathologists from different hospitals, Dr. Kevin Sandeman and Dr. Tuomas Mirtti, on their thoughts about the impact and benefits of AI and digital pathology in clinical diagnostics.
BLOG POST
5 reasons to use AI in clinical diagnostics
What additional benefit does AI bring to the digitized pathology workflow in clinical diagnostics? Read our article to find out.
NEWS
Aiforia obtains CE-IVD mark for AI-supported breast cancer diagnostics
Read our article to find out why the Aiforia Ki67 AI Model is a first-of-its kind diagnostic tool for pathologists to harness the full potential of their own expertise.
NEWS
Epredia and Aiforia announce partnership
We are thrilled to announce our partnership with Epredia, a global leader in precision cancer diagnostics, for the global distribution of our AI-powered pathology software!
NEWS
Aiforia and X-ZELL partner to scale up novel AI-powered method for early cancer detection
Aiforia partners with med-tech company X-ZELL to combine deep learning software with rare cell detection tech to build a novel, AI-powered method for early cancer detection.